When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?

Internal Medicine Journal

Volumn 42, Issue 4, 2012, Pages 450-455

  Bird, R J ^a   Kenealy, M ^c   Forsyth, C ^e   Wellwood, J ^b   Leahy, M F ^f   Seymour, J F ^d   To, L B ^g  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^c CABRINI HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Wyong Hospital   (Australia)

^f FREMANTLE HOSPITAL   (Australia)

^g UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Chelation; Iron; Myeodysplasia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON;

AGRANULOCYTOSIS; ARTICLE; BLOOD TRANSFUSION; BONE MARROW DISEASE; CLINICAL DECISION MAKING; DIARRHEA; ERYTHROCYTE; HEART DISEASE; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER DISEASE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RASH; SCORING SYSTEM;

CHELATION THERAPY; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 84859874087     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02734.x     Document Type: Article

References (31)

1. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN etal. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87: 1286-306.
2. Bowen D, Culligan D, Jowett S, Kelsey S, Mufti G, Oscier D etal. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200.
3. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, DeCastro CM etal. National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guidelines™). [homepage on the Internet]. Myelodysplastic Syndromes. Updated 21 December 2010 [cited 3 February 2011]. Available from URL:
4. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83: 858-61.
5. Leitch HA, Goodman TA, Wong KK, Vickars LM, Galbraith PF, Leger CS. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Blood 2006; 108: abstr 249.
6. Raptis A, Duh MS, Wang ST, Dial E, Fangourgiakis I, Fortner B etal. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anaemia: data from multicenter clinical practices. Transfusion 2010; 50: 190-9.
7. Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U etal. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only (ASH Annual Meeting Abstracts). Blood 2009; 114: 1747.
8. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A etal. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicentre study by the GFM. Leuk Res 2010; 34: 864-70.
9. Cabantchik ZI, Kakhlon O, Epsztejn S, Zanninelli G, Breuer W. Intracellular and extracellular labile iron pools. Adv Exp Med Biol 2002; 509: 55-75.
10. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL etal. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010; 28: 2847-52.
11. Takatoku M, Uchiyama T, Okamoto S, Kamakura Y, Sawada K, Tomonaga M etal. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anaemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-94.
12. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009; 25: 139-45.
13. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007; 31 (Suppl 3): S2-6.
14. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP etal. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-8.
15. Sanz G, Nomededeu B, Such E, Bernal T, Belkaid M, Ardanaz MT etal. Independent impact of iron overload and transfusion dependency on survival and leukaemic evolution in patients with myelodysplastic syndrome. Blood 2008; 112: abstr 640.
16. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R etal. Time dependent prognostic scoring system for predicting survival and leukaemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-10.
17. Malcovati L, Porta MG, Pascutto C. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-603.
18. Hershko C, Peto TE. Non-transferrin plasma iron. Br J Haematol 1987; 66: 149-51.
19. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009; 114: 5251-5.
20. Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T etal. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007; 138: 587-93.
21. Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, Eshet Y etal. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 2007; 82: 1013-16.
22. Di Tucci A, Matta G, Deplano S, Gabbas A, Depau C, Derudas D etal. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008; 93: 1385-8.
23. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003; 101: 4632-9.
24. Ibrahim AS. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008; 39: 743-6.
25. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T etal. The effect of iron chelation on haematopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-99.
26. Messa E, Cillonie D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120: 70-4.
27. Messa E, Carturan S, Maffe C, Pautasso M, Bracco E, Roetto A etal. Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemic cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010; 95: 1308-16.
28. Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C etal. Prospective assessment of the effects on iron overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010; 34: 1560-5.
29. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH etal. Cardiovascular T2-star magnetic resonance for the early detection of myocardial iron overload. Eur Heart J 2001; 22: 2171-9.
30. St Pierre TG, Clark PR, Chua-Anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK etal. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-61.
31. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y etal. T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Blood 2010; 115: 2364-71.